Xov Xwm Tuam Txhab
Lub Sijhawm Ua Tau Zoo ntawm CD19 CAR T-Cell Therapy hauv Kev Kho Mob Relapsed/Refractory Acute Lymphoblastic Leukemia
Ib txoj kev tshawb nrhiav pom pom qhov ua tiav ntev ntawm CD19 CAR T-cell txoj kev kho mob hauv kev kho cov neeg mob rov qab / refractory mob lymphoblastic leukemia (TAG NRHO) tom qab allogeneic hematopoietic qia cell transplantation, muab kev cia siab tshiab hauv hematology.
Bioocus Advances Frontier nyob rau hauv Kev Kho Mob Pediatric Acute Lymphoblastic Leukemia
Bioocus yog tus thawj coj ntawm kev tsim kho CAR-T tiam tom ntej. Cov ntawv tshaj tawm tsis ntev los no los ntawm Dr. Chunrong Tong thiab nws pab neeg hauv Tsev Kho Mob Lu Daopei qhia txog kev nce qib tseem ceeb thiab cov teeb meem hauv kev siv CD19 CAR-T tiam thib ob hauv cov neeg mob menyuam yaus, qhia txog Bioocus txoj kev mob siab rau kev kho mob qog noj ntshav tshiab.
Pioneering CAR-T Therapy hauv B-cell Acute Lymphoblastic Leukemia Qhia Txog Kev Ua Tau Zoo
Ib txoj kev tshawb nrhiav pom tau hais txog qhov ua tau zoo ntawm CAR-T cell therapy hauv kev kho B-cell Acute Lymphoblastic Leukemia (B-ALL). Kev tshawb fawb, koom nrog kev koom tes nrog BIOOCUS thiab Lu Daopei Tsev Kho Mob, qhia txog kev nce qib tseem ceeb, tsim txoj kev kho raws li qhov kev xaiv kho mob tseem ceeb.
Lub tswv yim CAR-T Cell Therapies Hloov Kho B Cell Malignancies
Cov kws tshawb fawb los ntawm Lu Daopei Tsev Kho Mob thiab cov neeg koom tes thoob ntiaj teb tshawb nrhiav cov kev kho mob CAR-T xov tooj ntawm tes, muab kev cia siab rau cov neeg mob uas muaj kab mob B cell. Txoj kev tshawb no qhia txog kev nce qib hauv kev tsim thiab kev siv, qhia cov txiaj ntsig tau zoo thiab muaj peev xwm rau kev tsim kho tshiab yav tom ntej.
Enhanced Antitumor Efficacy ntawm 4-1BB-raws li CD19 CAR-T Cells hauv Kev Kho B-ALL
Cov kev tshawb fawb soj ntsuam tsis ntev los no qhia tias 4-1BB-raws li CD19 CAR-T hlwb ua kom pom kev ua haujlwm zoo tshaj plaws antitumor piv rau CD28-based CAR-T hlwb hauv kev kho mob rov qab los yog refractory B cell mob lymphoblastic leukemia (r / r B-ALL).
Lu Daopei Tsev Kho Mob Kev Kho Mob Tsawg-Dose CD19 CAR-T Qhia Tau Zoo Tshaj Plaws hauv B-ALL Cov Neeg Mob
Ib txoj kev tshawb fawb tsis ntev los no ntawm Lu Daopei Tsev Kho Mob tau pom tias muaj kev ua tau zoo thiab kev nyab xeeb ntawm kev siv tshuaj tsawg CD19 CAR-T cell therapy hauv kev kho cov neeg mob refractory los yog rov qab los ntawm B mob lymphoblastic leukemia (B-ALL) cov neeg mob. Cov kev tshawb fawb, uas suav nrog 51 tus neeg mob, tau qhia txog qhov ua tiav kev tshem tawm zoo kawg nkaus nrog cov kev mob tshwm sim tsawg.
Novel Promoter Strategy Enhances Safety and Efficiency of CAR-T Therapy in Acute B Cell Leukemia
Lu Daopei Tsev Kho Mob thiab Hebei Senlang Biotechnology tau tshaj tawm cov txiaj ntsig kev tshawb pom los ntawm lawv txoj kev tshawb fawb tsis ntev los no txog kev nyab xeeb thiab kev ua tau zoo ntawm CAR-T kho rau mob B cell leukemia. Qhov kev sib koom tes no qhia txog lub peev xwm ntawm CAR-T xov tooj tshiab tsim los txhim kho cov txiaj ntsig ntawm tus neeg mob.
Kev Tshawb Fawb Txog Kev Tshawb Fawb Qhia Txog Kev Nyab Xeeb thiab Kev Ua Haujlwm ntawm CAR-T Kev Kho Mob hauv Kev Kho Mob B-Cell Malignancies
Ib txoj kev tshawb fawb tshiab coj los ntawm Dr. Zhi-tao Ying los ntawm Peking University Cancer Tsev Kho Mob tau qhia txog kev nyab xeeb thiab kev ua tau zoo ntawm IM19 CAR-T cell therapy hauv kev kho mob rov qab thiab refractory B-cell hematologic malignancies. Luam tawm nyob rau hauv lubSuav Journal of New Drugs, txoj kev tshawb fawb tau tshaj tawm tias 11 ntawm 12 tus neeg mob tau ua tiav kev tshem tawm yam tsis muaj kev cuam tshuam loj heev, qhia txog lub peev xwm ntawm IM19 raws li kev cog lus kev kho mob rau cov neeg mob uas tsis muaj lwm txoj hauv kev.
Ib xyoos ib zaug Clinical Blood Management thiab Transfusion Technology Training tuav ntawm Yanda Ludaopei Tsev Kho Mob
Xyoo 2024 Kev cob qhia txhua xyoo rau Kev Tswj Xyuas Ntshav Qab Zib thiab Kev Hloov Kho Tshuab hauv Sanhe City tau ua tiav hauv Tsev Kho Mob Yanda Ludaopei. Qhov kev tshwm sim no yog txhawm rau txhim kho kev tswj hwm ntshav thiab kev nyab xeeb ntawm cov ntshav los ntawm kev cob qhia kev kawm uas tau koom nrog ntau dua 100 tus kws kho mob los ntawm ntau lub tsev kho mob.
Txhawb Kev Noj Qab Haus Huv thiab Rov Qab Los: Kev Saib Xyuas Txhua Hnub rau Cov Neeg Mob Leukemia
Ua kom muaj kev nyab xeeb thiab xis nyob hauv kev kho mob rau cov neeg mob leukemia suav nrog kev saib xyuas txhua hnub, suav nrog kev huv huv ib puag ncig, kev tu tus kheej, khoom noj khoom haus, thiab kev tawm dag zog kom tsim nyog. Phau ntawv qhia no muab cov lus qhia tseem ceeb rau kev saib xyuas txhua hnub kom muaj txiaj ntsig zoo.
NS7CAR-T Cell Therapy Shows Promise for Treating R/R T-ALL/LBL
Ib txoj kev tshawb fawb tsis ntev los no qhia txog kev ua tau zoo thiab kev nyab xeeb ntawm NS7CAR-T cell therapy hauv kev kho mob rov qab los yog refractory T-cell mob lymphoblastic leukemia (R / R T-ALL) thiab T-cell lymphoblastic lymphoma (R / R T-LBL). Txoj kev kho no muab kev cia siab tshiab rau cov neeg mob uas muaj cov mob qog noj ntshav hnyav no.
Tshaj tawm 2024 Lub Rooj Sib Tham Lu Daopei Hematology Txhua Xyoo thaum Lub Yim Hli
Lub 12th Lub Rooj Sib Tham Lu Daopei Hematology tau teem sijhawm rau lub Yim Hli 23-24, 2024, ntawm Beijing International Convention Center. Koom nrog peb rau kev sib tham txog kev pom thiab kev nce qib tshiab hauv hematology.